Filtered By:
Condition: Pregnancy
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 1466 results found since Jan 2013.
Acute Ischemic Stroke in Pregnancy
ConclusionFetal safety concerns should not preclude routine diagnostic work-up (except for gadolinium contrast media administration) in childbearing AIS women, including procedures applied in unknown onset and late onset individuals. Due to rather low added risk of serious treatment complications, pregnancy should not be a sole contraindication for neither IVT, nor endovascular treatment.
Source: Clinical Neuroradiology - September 16, 2022 Category: Neurology Source Type: research
Temporal trends in pregnancy associated stroke: risk factors and associated outcomes, a national cohort
Our aim was to assess the temporal trend and to ascertain whether risks factors or adverse outcomes in the U.S. differed by timing of pregnancy associated stroke (antepartum versus postpartum).
Source: American Journal of Obstetrics and Gynecology - January 1, 2023 Category: OBGYN Authors: Ghamar Bitar, Han-Yang Chen, Sami Backley, Suneet P. Chauhan, Baha M. Sibai, Michal Fishel Bartal Tags: Poster Session II Source Type: research
Pregnancy associated stroke and hypertension: a national cohort evaluating temporal trends, risk factors, and mortality
Our aim was to evaluate the association between pregnancy associated stroke (PAS) and hypertensive disorder in the U.S.
Source: American Journal of Obstetrics and Gynecology - January 1, 2023 Category: OBGYN Authors: Ghamar Bitar, Baha M. Sibai, Han-Yang Chen, Sami Backley, Suneet P. Chauhan, Michal Fishel Bartal Tags: Poster Session II Source Type: research
AHA News: Pregnancy Complications Could Increase Woman ' s Stroke Risk at Earlier Age
THURSDAY, Feb. 2, 2023 (American Heart Association News) -- Women who have pregnancy-related health problems face an increased risk for having a stroke much earlier in life than their peers with uncomplicated pregnancies, a risk that climbs with...
Source: Drugs.com - Daily MedNews - February 2, 2023 Category: General Medicine Source Type: news
Pregnancy Complications Linked to Higher Stroke Risk for Women
MONDAY, May 22, 2023 -- Women who ’ve had certain pregnancy complications have significantly higher odds for a stroke than women with uncomplicated pregnancies, new research shows.
Moreover, these strokes may occur at a relatively early age,...
Source: Drugs.com - Daily MedNews - May 22, 2023 Category: General Medicine Source Type: news
Preeclampsia in Pregnancy Puts Black Women at Higher Odds for Stroke
TUESDAY, July 11, 2023 -- While preeclampsia and stroke during pregnancy are far more common in Black women in the United States, almost all study of links between these two conditions has been done on white women.
In a new study, researchers...
Source: Drugs.com - Daily MedNews - July 11, 2023 Category: General Medicine Source Type: news
Infertility Treatment May Put Women at Greater Risk for Stroke
THURSDAY, Aug. 31, 2023 – Scientists have spotted an elevated risk of stroke in women who became pregnant after fertility treatments.
Although the absolute number of strokes reported in the new study were low, women seeking fertility treatment...
Source: Drugs.com - Daily MedNews - August 31, 2023 Category: General Medicine Source Type: news
Factors influencing real-life use of direct oral anticoagulants in patients with cerebral sinus and venous thrombosis
Cerebral sinus and venous thrombosis (CSVT) is a rare subtype of stroke caused by thrombosis of the dural sinuses and cerebral veins which comprises 0.5 –1% of all strokes1,2. The annual incidence ranges from 0.22 to 1.57 per 100,000, most often affecting young adults with a median age of 35 years3-5. Among CSVT patients, the female-to-male ratio is 3:1 and women are significantly younger compared to men6. This is largely due to the increased risk of CSVT associated with oral contraceptives, pregnancy and the puerperium3,7,8.
Source: Journal of Stroke and Cerebrovascular Diseases - July 10, 2023 Category: Neurology Authors: Naaem Simaan, Jeremy Molad, Asaf Honig, Andrei Filioglo, Shlomi Peretz, Fadi Shbat, Tarek Mansor, Waleed Abu-shaheen, Ronen R. Leker Source Type: research
Substance Abuse Greatly Raises Odds of Heart Attack, Stroke During Pregnancy
THURSDAY, Sept. 21, 2023 -- Substance abuse and pregnancy may be a dangerous combination.
New research finds that pregnant women with a history of substance abuse had a dramatically increased risk of death from heart attack and stroke during...
Source: Drugs.com - Daily MedNews - September 21, 2023 Category: General Medicine Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Oversleeping: The Effects and Health Risks of Sleeping Too Much
This article originally appeared on the Amerisleep blog. Rosie Osmun is the Creative Content Manager at Amerisleep, a progressive memory foam mattress brand focused on eco-friendly sleep solutions. Rosie writes more posts on the Amerisleep blog about the science of sleep, eco-friendly living, leading a healthy lifestyle and more. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
Source: Healthy Living - The Huffington Post - January 29, 2016 Category: Consumer Health News Source Type: news
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
